Enveda raises $311M Series E at $2B valuation

AI biotech startup Enveda has raised a $311 million Series E led by Catalio Capital Management, valuing the company at $2 billion, doubling its valuation from a year ago. The company uses AI to discover drugs from nature and is currently testing drugs in patients for severe skin conditions and weight loss maintenance after stopping GLP-1s.

• Top 10 US funding rounds: cybersecurity and AI lead2026-09-25